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1. Introduction
In AD, a significant synaptic loss ranging from 20% to 50% is reported. Biochemistry, elec‐
tron microscopy and immunocytochemistry  have shown a  decrease  in  synaptic  density,
presynaptic  terminals,  synaptic  vesicle  and synaptic  protein markers in AD brains com‐
pared with the normal aged controls (Terry et al.,  1991; Geula, 1998; Larson et al.,  1999;
Yao et al., 1999; Ashe, 2000; Baloyannis et al., 2000; Terry, 2000; Masliah, 2001; Masliah et
al., 2001; Price et al., 2001; Scheff and Price, 2001; Scheff et al., 2001; Stephan et al., 2001;
Callahan et al., 2002; Chan et al., 2002; Dodd, 2002). Although synaptic loss is remarkable
in AD, it is not specific to AD. Reduction in synaptic density is also found in Pick’s dis‐
ease,  Huntington’s  disease,  Parkinson’s  disease  as  well  as  in  vascular  dementia  (Geula,
1998; Larson et al., 1999; Yao et al., 1999; Ashe, 2000; Baloyannis et al., 2000; Terry, 2000;
Masliah, 2001; Masliah et al.,  2001; Price et al.,  2001; Scheff and Price, 2001; Scheff et al.,
2001; Stephan et al., 2001; Callahan et al., 2002; Chan et al., 2002; Dodd, 2002).
Since one of the most important physiological functions of synapses is to release and ac‐
cept  neurotransmitters,  the  changes  of  activity  of  these  neurotransmitters  in  neurodege‐
nerative diseases have also been intensively studied (Terry, 2000). In AD, most significant
lesions happen in the cholinergic, adrenergic and serotoninergic systems (Davies and Ma‐
loney, 1976; Geula, 1998; Larson et al., 1999; Yao et al., 1999; Ashe, 2000; Baloyannis et al.,
2000; Terry, 2000; Masliah, 2001; Masliah et al.,  2001; Price et al.,  2001; Scheff and Price,
2001; Scheff et al., 2001; Stephan et al., 2001; Callahan et al., 2002; Chan et al., 2002; Dodd,
2002). Some other peptidergic neurotransmitters also decrease in AD, such as somatosta‐
tin, neuropeptide Y and substance P (Terry, 2000).
Synaptic loss might be one of the first events in AD development (Terry et al., 1991; Ter‐
ry,  2000;  Selkoe,  2002).  Decrease  in  presynaptic  terminals,  synaptic  vesicle  and synaptic
protein markers occur in very early stage of AD (Ashe, 2000; Terry, 2000; Masliah et al.,
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2001; Price et al.,  2001; Scheff et al.,  2001; Callahan et al.,  2002; Chan et al.,  2002; Dodd,
2002). In the transgenic mice with FAD mutations, synaptophysin, marker for presynaptic
protein, decreases before the appearance of Aβ deposits and formation of plaques (Hamos
et al., 1989; Masliah et al., 1989; Selkoe, 2002). Most important, the decline of function of
synaptic  transmission  occurs  even  before  synaptic  structural  changes  (Masliah,  2001;
Scheff  and Price,  2001;  Chan et  al.,  2002;  Selkoe,  2002).  Long-term potentiation (LTP)  is
commonly accepted as a measurement for capacity of synaptic plasticity, which is the ba‐
sis of learning, memory and complex information processing. The incidence and duration
of  LTP formation are  used as  an  indication for  formation and maintenance  of  working
memory. Several lines of FAD mutant transgenic mice show a decline in the formation of
LTP and synaptic excitation before the appearance of synaptic loss, plaques and other AD
pathology (Geula, 1998; Ashe, 2000; Masliah, 2001; Masliah et al.,  2001; Scheff and Price,
2001;  Callahan  et  al.,  2002;  Chan  et  al.,  2002;  Selkoe,  2002).  In  summary,  synaptic  loss
seems to appear earlier than all other pathological markers and the functional loss of syn‐
apses may be responsible for the initiation of cognitive decline in AD patients.
2. Neuronal loss in AD
Synaptic loss and degeneration induce neuronal dysfunction and cell body loss. Neuronal loss
in the cerebral cortex and the hippocampus is a hallmark feature of AD. Some of AD patients
at late stage of the disease can have a severe decrease in brain volume and weight due to either
neuronal loss or atrophy (Smale et al., 1995; Cotman and Su, 1996; Gomez-Isla et al., 1996;
Gomez-Isla et al., 1997; Li et al., 1997; Su et al., 1997; Gomez-Isla et al., 1999). Assumption-based
and design-based unbiased stereological cell counting show decreased density of neurons in
the cerebral cortex, the entorhinal cortex, the association cortex, the basal nucleus of Meynert,
the locus coeruleus and the dorsal raphe of AD brains (Bondareff et al., 1982; Lippa et al.,
1992; Gomez-Isla et al., 1996; Gomez-Isla et al., 1997; Gomez-Isla et al., 1999; Colle et al., 2000).
Profound neuronal loss is especially observed in the entorhinal cortex in the mild AD brains
(Gomez-Isla et al., 1996; Gomez-Isla et al., 1997; Gomez-Isla et al., 1999). Besides AD, significant
neuronal loss is also observed in the entorhinal cortex in very mild cognitive impairment
patient brains (Gomez-Isla et al., 1996; Gomez-Isla et al., 1997; Gomez-Isla et al., 1999). These
data suggest that neuronal loss may be one of the early events before formation of SPs and
NFTs in AD development.
The loss of cholinergic neurons in AD is widely studied. The hippocampus and cortex receive
major cholinergic input from the basal forebrain nuclei (Hohmann et al., 1987). Decrease of
choline acetyltransferase activity and acetylcholine synthesis correlate well with the degree of
cognitive impairment in AD patients (Mesulam, 1986; Hohmann et al., 1987; Pearson and
Powell, 1987). Cholinergic neuronal lesion can be detected in the patients that have showed
clinical memory loss symptoms for less than 1 year (Whitehouse et al., 1981; Whitehouse et al.,
1982; Francis et al., 1993; Weinstock, 1997). However, markers for dopamine, γ-aminobutyric
acid (GABA), or somatostatin are not altered (Whitehouse et al., 1981; Whitehouse et al.,
1982; Francis et al., 1993). These results suggest that cholinergic neuronal loss is probably one
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of the early events in AD. Besides the main pathology discussed above, some other pathologies
of AD include granulovacuolar degeneration, cerebral amyloid angiopathy, blood-brain
barrier disorder, white matter lesions, neuropil thread and gliosis (Jellinger, 2002a; Jellinger,
2002b, c; Jellinger and Attems, 2003).
As discussed above, stereological cell counting shows that densities of neurons in the AD
cerebral cortex, the entorhinal cortex, the association cortex, the basal nucleus of Meynert, the
locus coeruleus and the dorsal raphe decrease significantly compared to the age-matched non-
AD controls (Bondareff et al., 1982; Lippa et al., 1992; Gomez-Isla et al., 1996; Gomez-Isla et al.,
1997; Gomez-Isla et al., 1999; Colle et al., 2000). Neuronal cell loss is one of the first events
during AD development. In the mild AD patient brains, remarkable neuronal cell loss of more
than 40% is seen in the entorhinal cortex (Gomez-Isla et al., 1996; Gomez-Isla et al., 1997). Even
in the mild cognitive impairment patient brains, significant neuronal loss is also observed in
the entorhinal cortex (Gomez-Isla et al., 1996). Furthermore, the degree of neuronal loss
correlates better with the clinical dementia level in AD than other pathology.
It was thought until recently that neuronal loss is mainly due to passive neurotrophic factor
withdrawal. In 1988, Martin et al. (1988) showed that sympathetic neuronal death could be
prevented by inhibiting RNA and protein synthesis, indicating that some of the neuronal death
might be actively programmed (apoptotic) instead of passive (necrotic).
3. Apoptosis
Apoptosis, or programmed cell death (PCD), is a term proposed by Kerr, Wyllie and Currie
in 1972 (Kerr et al., 1972) to describe a common type of cell death characterized by membrane
blebbing, cell shrinkage, protein fragmentation, chromatin condensation and DNA degrada‐
tion followed by rapid engulfment of corpses by surrounding cells (Kerr et al., 1972). It rapidly
cleans out dysfunctional cells, limits toxic effects, saves energy and recycles molecules for
future de novo synthesis.
Two major apoptotic pathways in mammalian cells are mediated through either death re‐
ceptors or mitochondria (Figure 1). The so-called extrinsic pathway is initiated by death re‐
ceptor  CD95 (Apo-1/Fas),  or  other  death receptors,  such as  tumor necrosis  factor  (TNF)
receptor  and  tumor  necrosis  factor  related  apoptosis  inducing  ligand  (TRAIL)  receptor.
CD95 is linked to pro-caspase-8 by an adapter factor FADD. Pro-caspase-8 has a death ef‐
fecter  domain (DED) which binds to  the death domain (DD) on death receptor  adapter
FADD, and a caspase activation and recruitment domain (CARD),  which binds to other
downstream caspases and further processes the downstream caspases. Ligand binding sig‐
nals the activation of pro-caspase-8 to form a tetramer of active caspase-8. Caspase-8 then
mediates the cleavage of pro-caspase-3 and initiates the caspase activation cascade, which
leads to protein and DNA cleavage and final termination of the cells. In this pathway, cas‐
pase-8 activation can be prevented by its natural inhibitors, such as cellular FADD-like in‐
terlukin-1-β-converting enzyme (FLICE/caspase-8)-inhibitory proteins  (c-FLIPs)  (Irmler  et
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al.,  1997;  Thome et  al.,  1997)  and apoptosis  repressor  with  caspase  recruitment  domain
(ARC) (Koseki et al., 1998) (Figure 1).
The intrinsic pathway is triggered mainly by internal insults such as DNA damage. Dam‐
aging insults such as UV irradiation activate tumor suppression gene product p53, a tran‐
scriptional factor. There are several hypotheses for p53 activation mechanism. First, stress-
activated  protein  kinases,  such  as  DNA-dependent  protein  kinase  (DNA-PK),
phosphorylates  p53.  This  phosphorylation prevents  p53 from degradation.  For  example,
DNA-PK can be activated by DNA damage, and then phosphorylate p53 at Ser-15 in the N
terminal, which prevents the interaction between p53 and its inhibitory protein MDM-2. In
addition  to  phosphorylation,  dephosphorylation,  such  as  the  one  caused  by  14-3-3  at
Ser-376, can also enable DNA binding of p53 and activate its function. The second model
states that p53 is constitutively active and is regulated by the negative regulator MDM-2.
MDM-2 protein can bind to p53 and send it out of the nucleus for degradation. Interesting‐
ly, the MDM-2 gene can be activated by p53, therefore, p53 is negatively self-regulated. Af‐
ter activation, p53 acts as a transcriptional factor controlling the expression of certain genes.
These  genes  are  involved in  cell  cycle  control  (eg.  p21,  GADD45,  14-3-3,  CyclinD1,  Cy‐
clinG), DNA repair (eg. GADD45, p21), apoptosis (eg. Bax, Bcl-2, FASL, DR5), angiogenesis
(eg. TSP-1, BAI1) and cellular stress response (eg. TP53TG1, CSR, PIG3).
During apoptosis,  p53  activates  transcription of  the  pro-apoptotic  Bax and,  at  the  same
time, transcriptionally represses the anti-apoptotic Bcl-2. A family of Bcl-2 proteins is impli‐
cated in apoptosis. This family contains three subgroups of proteins, some of them are pro-
apoptotic  while  some  are  anti-apoptotic.  The  Group  I  proteins,  such  as  Bcl-2,  have  a
transmembrane domain and conserved Bcl-2 homology (BH) 1-4 domains.  The Group II
lacks the BH4 domain, such as Bax, while in the Group III, only the BH3 domain is in com‐
mon, such as Bid and Bik (Hengartner, 2000). Bax is a pro-apoptotic protein causing the de‐
polarization  of  mitochondrial  membrane  and  release  of  cytochrome  c  from  the
mitochondria to the cytosol. The detailed mechanism of Bax leading to cytochrome c re‐
lease is unknown. Bax is located in the cytosol as monomers and upon the apoptotic stimu‐
lation,  Bax oligomerizes  and translocates  to  the  mitochondria.  There  are  several  models
suggested to explain how Bax oligomers cause intermembrane protein cytochrome c  re‐
lease (Degli Esposti and Dive, 2003). First, Bax oligomers may form a pore structure on the
mitochondria  outer  membrane  leading  to  cytochrome  c  release.  Second,  interaction  be‐
tween Bax and other  mitochondrial  proteins,  such as  voltage dependent  anion selective
channel (VDAC) and adenosine nucleotide transporter (ANT) may induce pore formation
by VDAC and ANT, through which cytochrome c is released. Third, the pore may form on
the  membrane  by  low-selective  ion  channels  and  induce  cytochrome  c  release  through
these channels  (Degli  Esposti  and Dive,  2003).  Cytochrome c,  together  with the adapter
molecule Apaf-1 and pro-caspase-9, forms an apoptosome that cleaves pro-caspase-3 into
its active form and initiates apoptosis. Bcl-2, the other member of Bcl-2 family in the Group
I, is an anti-apoptotic protein preventing Bax-mediated cytochrome c release efficiently.
The two apoptotic pathways cross at Bid, a pro-apoptotic protein from Bcl-2 family Group
III. Bid can be cleaved by active caspase-8 and the truncated Bid translocates to the mito‐
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chondrial  membrane,  increases  mitochondrial  outer  membrane  permeability,  facilitates
pore  formation  and  potentiates  cytochrome  c  release  on  the  mitochondrial  outer  mem‐
brane (Figure 1) (Hengartner, 2000).
This apoptosis machinery is self-amplifying. For example, second mitochondria-derived
activator of caspase/direct IAP-binding protein with low pI (Smac/DIABLO) and apoptosis-
inducing factor (AIF) proteins (Hengartner, 2000; Cregan et al., 2002) are released from the
mitochondria with cytochrome c to facilitate apoptosis. In addition, recent studies showed that
caspase-3, -6, -7 and –8 can initiate cytochrome c release by activating cytosolic factors (Figure
1). Since cytochrome c acts as an initiator for the caspase activation cascade, this self-amplified
loop facilitates cellular apoptosis (Figure 1) (Bossy-Wetzel and Green, 1999).
CD95
FADD
Procaspase-8
Active caspase-8
c-FLIP
Bid
Truncated bidProcaspase-3, -6, -7
Active caspase-3, -6, -7
Apoptotic substrates
DNA damage
p53
Bax
mitochondria
Cytochrome c
Procaspase-9
Apaf-1
AIF
Bcl-2
Bcl-xL
Smac/DIABLOIAPs
Apoptosome
Intrinsic pathwayExtrinsic pathway
Figure 1. Schematic drawing of two major pathways involved in apoptosis. Schematic digram showing the two major
pathways mediating apoptosis. The extrinsic pathway is mediated by death receptors, such as FADD, and caspase-8
activation. The intrinsic pathway is induced by DNA damage and mediated by caspase-9. IAP: inhibitor of apoptosis
protein, Smac/DIABLO: second mitochondria-derived activator of caspase/direct IAP-binding protein with low pI, AIF:
apoptosis inducing factor.
Caspases in Alzheimer’s Disease
http://dx.doi.org/10.5772/54627
129
4. Apoptosis involvement in neuronal cell loss of AD
There is evidence for apoptosis involvement in neuronal loss in AD, but the evidence so far
is not sufficient to support a significant role for apoptosis in the neuronal cell loss in AD.
Evidence of apoptosis in AD is as follows. First, overexpression of FAD-related mutations
causes apoptosis in the transfected cell lines, cultured neurons and transgenic mice. For ex‐
ample, overexpression of FAD mutations of APPV642I, APPV642F and APPV642G in COS or F11
cells increases number of apoptotic cells as determined by DNA fragmentation and termi‐
nal dUTP nick end labeling (TUNEL) staining assay, which can be inhibited by anti-apop‐
totic protein Bcl-2 overexpression (Yamatsuji et al., 1996). These results support the role of
FAD mutations in inducing apoptosis. Similarly, the data from transgenic mice confirm the
above observations. Transgenic mice overexpressing FAD mutant APPV717F develop neuritic
dystrophy similar to some pathological features in AD patients (Games et al.,  1995; Hol‐
comb et al., 1998). The degenerating neurons in these mice also show typical apoptotic fea‐
tures,  such  as  chromatin  segmentation  and condensation,  and positive  TUNEL staining
(Nijhawan et al., 2000). However, in these studies, the FAD mutant proteins are normally
overexpressed far beyond the physiological levels. However, FAD neurons do not necessa‐
rily undergo apoptosis. In the mutant PS1 expressing neurons, increased apoptosis is not
reported (Bursztajn et al., 1998). Also, there is no neuronal loss found in mutant PS1 trans‐
genic mice (Takeuchi et al., 2000).
Second, some studies indicate apoptosis in AD patient brains using in situ detection of DNA
fragmentation by TUNEL staining (Su et al., 1994; Dragunow et al., 1995; Lassmann et al.,
1995; Smale et al., 1995; Anderson et al., 1996; Su et al., 1996; Troncoso et al., 1996; Gervais et
al., 1999; Anderson et al., 2000). However, in the AD brain tissues, some TUNEL-positive
neurons show typical apoptotic morphology whereas some do not, suggesting degenerating
neurons in AD may undergo both apoptosis and passive cell death, necrosis (Su et al., 1994;
Troncoso et al., 1996; Lucassen et al., 1997; Yuan and Yankner, 2000). It is now commonly
accepted that TUNEL staining sometimes is not specific to apoptosis (Stadelmann et al.,
1998). The staining of TUNEL may indicate increased vulnerability of cells to a secondary
insult, not necessarily undergoing apoptosis. On the other hand, the number of apoptotic
neurons is difficult to measure precisely due to the chronic nature, relatively long progress of
the disease and rapid clearance mechanism of dead cells.
Third, there are reports of changes of expression of apoptosis related proteins, such as p53,
Bcl-2 and Bcl-xL, in AD brains (Paradis et al., 1996; Kitamura et al., 1997; MacGibbon et al.,
1997; Su et al., 1997; Cotman, 1998; Torp et al., 1998; Tortosa et al., 1998). For example, pro-
apoptotic protein p53 is increased in AD brains (Kitamura et al., 1997), while anti-apoptotic
proteins Bcl-2 and Bcl-xL are decreased in AD brains (Kitamura et al., 1998; Tortosa et al.,
1998). Also, another pro-apoptotic protein Bax is increased in AD brains (Paradis et al., 1996;
Kitamura et al., 1997; MacGibbon et al., 1997; Su et al., 1997; Cotman, 1998; Torp et al., 1998;
Tortosa et al., 1998). However, the regulation of these pro- or anti-apoptotic proteins could be
primary or secondary response to insults. On the other hand, the upregulation of either pro-
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or anti-apoptotic proteins could be explained by either the neurons undergoing apoptosis or
neurons responding against apoptotic insults to prevent initiation of apoptosis.
Therefore, in summary, to date, there is no strong evidence showing significant involvement
of apoptosis in AD neuronal loss. Since caspases, a family of cysteinyl proteases, play an
important role in cell death, especially in apoptosis as discussed in the previous section
(Thompson, 1995; Strasser et al., 2000; Yuan and Yankner, 2000), it is of interest to identify
which caspase is responsible for human neuronal cell loss, how it is regulated, and whether it
can be inhibited. In addition, caspase activation may be easier to use for identification of
apoptosis since it is an upstream event of DNA fragmentation. Therefore, the apoptotic cells
have not been cleared yet.
5. Caspase involvement in apoptosis and APP metabolism in AD
5.1. Caspases
Caspases (cysteinyl aspartate-specific proteases) belong to a cysteinyl protease family that
cleaves specifically after an aspartic acid. To date, 14 caspases (11 of them are found in human)
have been identified in mammals. The connection between apoptosis and caspases was first
reported by Yuan et al. (1993) that caspase-1 is a homolog to CED-3, a gene regulating cell
death in Caenorhaditis elegans (Yuan et al., 1993). The important role of caspases in apoptosis is
also supported by the strong correlation between caspase activity and apoptosis in various cell
types. Furthermore, caspase inhibition prevents apoptosis both in vitro and in vivo (Yuan et al.,
1993; Kuida et al., 1995; Schwartz and Milligan, 1996; Alnemri, 1997; Thornberry, 1997; Li and
Yuan, 1999; Yuan and Yankner, 2000).
Inactive caspases contain a pro-domain,  a large subunit  and a small  subunit.  According
to  their  pro-domain  structure  and  function,  caspases  are  divided  into  “inflammatory”,
“initiator” and “effecter” caspases (Figure 2A) (Nicholson,  1999;  Hengartner,  2000).  Cas‐
pases are normally present  as  inactive precursors  in cells.  After  receiving apoptotic  sig‐
nals, caspase pro-enzymes undergo proteolytic processing to remove the N terminal pro-
domain  and  cleave  between  large  and  small  subunits  to  produce  the  active  form  of  a
tetrameric enzyme formed by 2 copies of  the large subunit  and 2 copies of  small  subu‐
nit.  To  date,  three  caspase  activation pathways  are  known in  mammalian cells:  recruit‐
ment-activation,  trans-activation  and  autoactivation  (Nicholson,  1999).  Recruitment-
activation  is  triggered  by  death  receptors  of  the  tumor  necrosis  factor  receptor  family.
The so-called initiator caspases, namely caspase-2, -8, -9 and –10 (Figure 3A), are thought
to be directly activated through the signals from death receptor (Boldin et al.,  1996; Mu‐
zio et al.,  1996). In addition, more recent data show that the initiator caspase-8, -9 and –
10  can  be  activated  by  homodimerization  of  their  monomeric  zymogens,  a  so  called
“proximity-induced activation” (Boatright et al.,  2003).  Trans-activation occurs through
downstream or executioner caspases, caspase-3, -6 and –7 that can be activated by direct
proteolysis by their upstream initiator caspases. By such trans-activation cascade, apopto‐
sis is well controlled and regulated (Darmon et al.,  1995; Martin et al.,  1996; Andrade et
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al.,  1998).  Caspase activation can also occur by activation of the dormant enzyme mole‐
cule  by the already active  one (autoactivation).  The supporting evidence of  this  mecha‐
nism comes from the observation that  arginine-glycine-aspartate (RGD) motif-containing
peptides  can  induce  caspase-3  autoactivation  by  triggering  conformational  changes  of
pro-caspase-3 (Buckley et al., 1999). A similar mechanism has been suggested for pro-cas‐
pase-8 and –2 activation (Hengartner, 2000).
Active Caspase-6
Prodomain Large domain Small domain
Inactive Proenzyme Caspase-6
Group I
Inflammation
Group II
Initiation
Group III
Execution
Caspase-1
Caspase-4
Caspase-5
Caspase-13
Caspase-2
Caspase-8
Caspase-9
Caspase-10
Caspase-3
Caspase-6
Caspase-7
Caspase-14
A
B
C
Csp-6 like Csp-6 like Csp-6 like
A TMAPP
Figure 2. Caspases are cysteinyl proteases responsible for protein degradation during apoptosis. A. Schematic dia‐
gram of caspase category according to function. There are three groups of caspases according to their basic functions:
inflammation, initiation and execution. B. Schematic drawing of pro-caspase-6 activation into active caspase-6. Cas‐
pase-6 activation by cleavage at the sites between pro-domain and large subunit (p20) as well as large subunit and
small subunit (p10). Arrow head: cleavage. C. Schematic drawing of caspase-6-like cleavage sites on APP. There are
three caspase-6-like cleavage sites on APP. Arrow: cleavage. TM: transmembrane domain.
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After activation, caspases recognize four amino acid substrate sites as their targets and cleave
the C terminal to an obligatory aspartic acid (XXXD). According to their specific substrates,
caspases are divided into 3 groups: caspase-1, -4, -5 and –13 (substrates: WEHD and YVAD);
caspase-2, -3 and -7 (substrate: DEXD) and caspase-6, -8, –9 and -10 (substrates: (I, V, L)EXD)
(reviewed by (Thornberry, 1997)). Once activated, caspases cleave downstream substrates in
a highly specific and rapid manner. More than 250 substrates are found including downstream
caspases or apoptosis-related proteins (e.g. Bid, Bcl-2), structural proteins (e.g. lamins, actin,
fodrin, gelsolin), DNA repair proteins (e.g. PARP, p21) and some other proteins involved in
neurodegenerative diseases (eg. APP, tau, PSs, Huntingtin) (reviewed by (Bounhar et al., 2002).
Most of the morphological changes in apoptosis described by Kerr et al. (1972) are caused by
caspases that are activated specifically in PCD. Caspase cleavage of nuclear lamins results in
nuclear shrinking and blebbing (McCarthy et al., 1997; Sakahira et al., 1998). Loss of cell
structure may be due to caspase cleavage of cytoskeletal proteins, such as fodrin (Vanags et
al., 1996; Janicke et al., 1998) and gelsolin (Kothakota et al., 1997). DNA fragmentation is also
caused by caspase-activated DNase (CAD), which is activated by caspases through removing
the inhibitory subunit (ICAD) from the inactive CAD enzyme complex (Hengartner, 2000).
5.2. Involvement of caspases in neuronal loss in AD
In general, the evidence supporting the involvement of caspases in neuronal loss in AD is still
not conclusive. The involvement of caspases in AD is first suggested by the finding that
caspases, acting as proteases, are involved in PSs and APP metabolism and Aβ peptide
generation in AD. Caspase-3 directly cleaves PSs during apoptosis (Kim et al., 1997). Caspase-3,
-6, -7, -8 and –9 can cleave APP and generate Aβ or Aβ-containing fragments, therefore, giving
a possibility of Aβ accumulation in AD (Barnes et al., 1998; Gervais et al., 1999; LeBlanc et al.,
1999; Pellegrini et al., 1999; Weidemann et al., 1999). In chick motor neurons, caspase-3 cleaves
APP and generates Aβ products (Barnes et al., 1998). In human 293 cells, caspase-9 cleaves
APP at the C terminal and produces a “C31” peptide, which is cytotoxic to cells (Lu et al.,
2000). Caspase-3 cleaves APP in NT-2 cells and is involved in Aβ formation (Gervais et al.,
1999). APP is a caspase substrate in staurosporine-treated NT-2 cells and Fas-treated human
Jurkat cells (Pellegrini et al., 1999). In addition, caspase inhibitors can prevent the formation
of Aβ (Barnes et al., 1998; Gervais et al., 1999; LeBlanc et al., 1999).
Second, more direct proof of caspase involvement in AD comes from immuno-detection of
active caspases in AD brain tissues, although the evidence is not sufficient enough to be
conclusive. Some studies have shown the activation of caspase-8 in AD brains (Rohn et al.,
2001; Rohn et al., 2002), while others found decreased level of caspase-8 in AD brains
(Engidawork et al., 2001a). In yet another study, both inactive and active caspase-8 immunor‐
eactivity are not changed in AD compared to control brains (Engidawork et al., 2001b). The
cleavage fragment of caspase-9 is also detected in AD but not in the control brains (Lu et al.,
2000; Goyal, 2001; Rohn et al., 2002), but the alteration of two caspase-9 activation co-factors,
Apaf-1 and cytochrome c, is not detected (Engidawork et al., 2001b). Furthermore, there is
recent evidence showing that pro-caspase-9 is activated through dimerization, but not
cleavage (Boatright et al., 2003). Among all caspases, caspase-3 is the most intensively studied
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since the caspase-3 knockouts develop abnormal brains with significantly excessive numbers
of neurons (Cregan et al., 1999; Keramaris et al., 2000; Simpson et al., 2001; Fernando et al.,
2002). Some studies report increased caspase-3-like immunoreactivity in AD brains (Masliah
et al., 1998; Gervais et al., 1999). However, the protein and mRNA levels of caspase-3 do not
appear altered in AD compared to control brains (Desjardins and Ledoux, 1998; LeBlanc et al.,
1999). Active caspase-3 is detected in granulovacuolar degeneration, an aging associated
pathology that is not necessarily specific to AD (Stadelmann et al., 1999; Roth, 2001). Given
that apoptosis results in a rapid clearance of dysfunctional cells, only small amount of caspase
activation can be detected at a certain time window. Therefore, the extensive detection of active
caspase-3 in some studies may be due to lack of immunospecificity of the caspase-3 antibody.
Furthermore, although caspase-3 is critical for apoptosis in many cell types, it does not have
significant role in the human neuronal loss in AD (Desjardins and Ledoux, 1998; LeBlanc et
al., 1999; Selznick et al., 1999; Stadelmann et al., 1999).
Interestingly, LeBlanc et al. have shown that caspase-6 is activated in serum deprivation
induced cell death of human neurons in primary cultured (LeBlanc et al., 1999). Therefore,
could caspase-6 be the responsible caspase in human neuronal cell death in AD?
5.3. Caspase-6 is activated during human neuronal cell death
5.3.1. Introduction to caspase-6
Caspase-6 (Mch-2), located on human chromosome 4q25, is an “effecter” caspase with a short
pro-domain. It recognizes VEID substrates and cleaves after the amino acid D. Its common
substrates include APP (LeBlanc et al., 1999), cytoskeleton proteins, such as keratin 18 (Caulin
et al., 1997), focal adhesion kinase (Gervais et al., 1998), tau (LeBlanc et al., 1999), β-catenin
(Van de Craen et al., 1999), vimentin (Byun et al., 2001) and desmin (Chen et al., 2003), nuclear
proteins, such as lamin A (Ruchaud et al., 2002), lamin B (Slee et al., 2001), PARP (Fernandes-
Alnemri et al., 1995), DNA topoisomerase I (Samejima et al., 1999) and emerin (Columbaro et
al., 2001), several transcriptional factors, such as SATB1, and AP-2α (Galande et al., 2001;
Nyormoi et al., 2001). It is highly expressed in the heart, lung, liver, kidney and testis in murine
tissues. There is immunodetectable caspase-6 in human brain and neurons (LeBlanc et al.,
1999; Zheng et al., 1999; Harrison et al., 2001). Caspase-6 can be activated by caspase-1, -3, -7,
-8 and –11 (Fernandes-Alnemri et al., 1995; Chinnaiyan et al., 1996; Orth et al., 1996). Pro-
caspase-6 is a ~ 34 kDa protein, that can be cleaved into ~20 kDa (p20) and ~10 kDa (p10)
fragments. The p20 and p10 fragments form a tetramer, which is the active form of the enzyme
(Figure 3C) (Fernandes-Alnemri et al., 1995). Caspase-6 knockout mice do not show abnormal
phenotype during development, which does not rule out the role of caspase-6 in cell death in
later stage of life or under stress conditions (Zheng et al., 1999).
5.3.2. Caspase-6 involvement in human neuronal cell death and APP processing
Pro-caspase-6 decreases during apoptosis induced by serum deprivation in human neurons
in primary cultures (LeBlanc et al., 1999). Moreover, caspase-6 active 10 kDa fragments is
detected only in AD brains, and not in the normal aging control brains (LeBlanc et al., 1999),
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although thus increase is not dramatic. Given that AD is a long progressive disease, at a certain
postmortem time window, there is only limited amount of cell death where caspase activation
can be detected. Meanwhile, in contrast to caspase-6, changes in the levels of pro- and active
caspase-3 levels are not detectable in AD brains, suggesting that caspase-6, but not caspase-3,
may be involved in human neuronal cell death (LeBlanc et al., 1999). Caspase-6 can also alter
APP metabolism to generate Aβ-containing fragments. There are several caspase-6-like sites
on APP695 (Figure 2C). However, incubating recombinant caspase-6 and APP695-containing
neuronal extract does not show APP cleavage. One of these cleavages at 591VKMD594 generates
a 6.5 kDa fragment denoted “Capp6.5” containing the Aβ sequence (Figure 2C) (LeBlanc et al.,
1999). Although caspase-6 does not directly induce 4 kDa Aβ, pulse-chase experiments showed
that this Capp6.5 fragment is able to generate 4 kDa Aβ in human neurons (Figure 2C) (LeBlanc
et al., 1999). Caspase-6 can cleave APP close to β-secretase site at D653 to further generate Aβ2-40
or Aβ2-42 (Gervais et al., 1999). In the Swedish mutation of APP, which changes the VKMD653
sequence at the β-secretase site to VNLD653, the caspase-6 cleavage of VNLD-AMC is 6 fold
higher than the VKMD-AMC fluorogenic peptide in vitro (Gervais et al., 1999). Also, caspase-6
can cleave APP after the γ-secretase site at VEVD720/A (Gervais et al., 1999). Therefore,
caspase-6 may process APP similar to β- and γ-secretase activity. Direct microinjecting
caspase-6 into human neurons induces dramatic cell death (Zhang et al., 2000). Taken together,
the above evidence suggests that caspase-6 plays important role in human neuronal cell death,
Aβ formation, and may be responsible for neuronal loss in AD (LeBlanc et al., 1999).
5.4. Inhibition of active caspases
5.4.1. Natural inhibitors to caspases
The natural inhibitors to caspases include Cowpox virus product cytokine response modifier
A (crmA), FLIPs, protease inhibitor 9 (PI-9), p35, ARC and inhibitor of apoptosis proteins
(IAPs). CrmA is a member of serpin family, a group of serine protease inhibitors. CrmA inhibits
caspases by acting as a pseudosubstrate that binds to active caspases, such as caspase-1, -4, -5,
-8 and –9 (Ray et al., 1992; Komiyana et al., 1994). Besides crmA, FLIPs inhibits caspase-8 by
acting as the dominant negative form to suppress caspase-8 mRNA expression (Thornberry,
1997). The mammalian homolog of crmA is PI-9. PI-9 mRNA expression can be rapidly induced
by estrogen in human liver (Kanamori et al., 2000). PI-9 is a granzyme B inhibitor (GBI).
Granzyme B is a 30 to 32 kDa serine protease, which cleaves peptides at aspartyl residue in
the killer T thymocytes and natural killer cells. Granzyme B is involved in the perforation of
target cells and then initiation of proteolysis that leads to apoptosis. Although PI-9 can inhibit
granzyme B and granzyme B-mediated apoptosis, In vitro experiments do not show that PI-9
inhibits active caspases (Bird et al., 1998; Bird, 1999).
p35 is a baculoviral protein that can block the defensive apoptotic response of insect cells
to viral infection (Clem et al., 1991; Ekert et al., 1999). p35 inhibits CED-3 in C. elegans and
mammalian caspase-1, -3, -6, -7, -8 and -10 (Ekert et al., 1999). P35 is cleaved at its P1 resi‐
due by caspases, and the cleaved fragment forms an inhibitory complex to block caspase
activation (Zhou et  al.,  1998).  ARC interacts  with caspase-2,  -8  and CED-3,  but  not  cas‐
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pase-1, -3, or –9. ARC inhibits caspase-8 enzyme activity in 293 cells, and further attenu‐
ates  apoptosis  induced  by  FADD  through  stimulation  of  death  receptors  coupled  with
pro-caspase-8 (Koseki et al., 1998).
IAPs were found in a search for viral genes with a similar function to p35. A group of cellular
IAP homologs are found in yeast, C. elegans, Drosophila and vertebrates (Ekert et al., 1999). To
date, the IAP family contains about a dozen proteins from viruses, Drosophila, mice and
humans. All known IAPs share a baculovirus inhibitory repeat (BIR) domain, which contains
a number of conserved residues including a zinc-binding region. Most of the IAPs also contain
a RING zinc-binding finger motif at the C terminal. Both BIR motifs and RING finger are
important for IAP function (Ekert et al., 1999). The neuronal apoptosis inhibitory protein
(NAIP) in human was found by searching for mutations in spinal muscular atrophy (SMA),
which is characterized by degeneration of the anterior horn cells in the spinal cord. The NAIP
gene is deleted in the SMA patients. During development, excessive neurons are ultimately
needed to send out axons, the neurons do not target properly undergo apoptosis. It is suggested
that NAIP is involved by preventing apoptosis in the “successful” cells (Miller, 1997).
The most studied IAP is the X-linked IAP (XIAP). XIAP binds to active caspase-9 small subunit
through its BIR3 domain and cleaves the small subunit to inactivate caspase-9 (Srinivasula et
al., 2001). On the other hand, XIAP binds to active caspase-3 or –7 through BIR2 domain and
mask the active site of these caspases (Huang et al., 2001; Riedl et al., 2001; Stennicke et al.,
2002). In addition, evidence shows that in insects, some IAPs interact with apoptosis-related
proteins, such as Grim, Reaper and Hid (Hay et al., 1995; Miller, 1997; Vucic et al., 1997; Vucic
et al., 1998). IAPs can also inhibit caspase-3 directly and cytochrome c-induced caspase-9
(Deveraux et al., 1998). However, up to now, although IAPs may inhibit caspase-6 activation
by blocking upstream caspase-9 or –3 activation (Deveraux et al., 1998), there is no evidence
showing that mammalian IAPs directly inhibit active caspase-6 enzyme activity.
5.4.2. Synthetic inhibitors to active caspases
Synthetic caspase inhibitors function as pseudosubstrates for active caspases and therefore,
they are competitive inhibitors of active caspases (Ekert et al., 1999). The N terminal blocking
groups of the pseudosubstrate peptides are usually acetyl- (Ac-) or benzocarbonyl (Z-). The
biochemical property of these synthetic inhibitors depends on the chemical group linked to
pseudosubstrate peptides. Aldehyde (CHO-) group inhibitors are reversible since there is no
covalent bond formed between these inhibitors and caspases. These CHO inhibitors have poor
cell membrane permeability, which limits largely the use of these inhibitors on live cells and
animals (Schotte et al., 1999; Bounhar et al., 2002). The inhibitors linked to methylketone
(chloromethylketone, cmk or fluoromethylketone, fmk) irreversibly inhibit caspases due to the
formation of thyomethylketone bonds with the cysteine in the active site of caspases (Bounhar
et al., 2002). These inhibitors are membrane permeable, but have less specificity of inhibitory
action to caspases (Schotte et al., 1999; Bounhar et al., 2002).
Although synthetic caspase inhibitors are widely used in research, they may not be the ideal
candidates for disease treatment since these inhibitors cannot inhibit caspase activation in
specific certain cell types. For example, in AD, caspase-6 is the key caspase responsible for
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neuronal loss. If the synthetic caspase-6 inhibitor is applied and it would inhibit active
caspase-6 activity in all types of cells, which has a large potential to develop cancer in cells that
proliferate. If a natural inhibitor to active caspase-6 can be activated somehow specifically in
human neurons, the risk of oncogenesis in the brain would be greatly reduced.
Since neuronal  loss  is  a  striking feature of  AD, decreasing or  suppressing neuronal  cell
loss may benefit early AD patients in retaining cognitive capacities and prevent or delay
disease progression. Caspases seem to play a significant role in human neuronal cell loss
in AD, thus it is intriguing to determine if caspase activity can be inhibited after activa‐
tion by neuroprotective agents.
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